Atara Biotherapeutics Inc. (NASDAQ:ATRA) finished Friday with a subtraction of -$0.09 to close at $2.09, a downside of -4.13 percent. An average of 1,243,940 shares of common stock have been traded in the last five days. There was a fall of -$0.21 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,196,730 shares traded, while the 50-day average volume stands at 1,814,378.
ATRA stock has increased by 5.03% in the last month. The company shares reached their 1-month lowest point of $1.78 on 07/17/23. With the stock rallying to its 52-week high on 02/06/23, shares of the company touched a low of $1.45 and a high of $5.94 in 52 weeks. It has reached a new high 14 times so far this year and lost -36.28% or -$1.19 in price. In spite of this, the price is down -64.81% from the 52-week high.
ATRA stock investors should be aware that Atara Biotherapeutics Inc. (ATRA) stock had its last reported insider trading activity 46 days ago on Jun 27. In this transaction, the insider spent $23,723. President and CEO, Touchon Pascal, disposed of 29,766 shares at a price of $2.04 on May 16. The insider now owns more than $60,633 worth of shares. Prior to that, EVP, Chief Technical Officer Banard Charlene A. went on to Sale 19,040 shares at $2.04 each on May 16. An amount of $38,784 was transacted.
Atara Biotherapeutics Inc. (ATRA) stock’s beta is 0.97. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.58, the price-to-book (PB) ratio at 3.37.
The quick ratio of Atara Biotherapeutics Inc. for the three months ended June 29 was 3.20, and the current ratio was 3.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.01 for the quarter ending June 29. Atara Biotherapeutics Inc.’s EBITDA margin for the year ending June 29 is -408.95%. Its gross profit as reported stood at $344.09 million compared to revenue of $63.57 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Atara Biotherapeutics Inc.’s return on assets was -58.00%.
For the three-month period that ended June 29, Atara Biotherapeutics Inc. had $107.74 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$71.11 million in the quarter, while revenues of -$74.77 million were shrunk -23.91%. The analyst consensus anticipated Atara Biotherapeutics Inc.’s latest quarter earnings to come in at -$0.67 per share, but it turned out to be -$0.68, a -1.50% surprise. For the quarter, EBITDA amounted to -$70.97 million. Shareholders own equity worth $101.1 million.
From a technical analysis perspective, let’s take a brief look at Atara Biotherapeutics Inc. (ATRA) price momentum. RSI 9-day as of the close on 11 August was 49.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 139.77%.
As of today, ATRA’s price is $2.13 -9.13% or -$0.21 from its 5-day moving average. ATRA is currently trading +14.21% higher than its 20-day SMA and -29.87% lower than its 100-day SMA. However, the stock’s current price level is +36.60% above the SMA50 and -52.50% below the SMA200.
The stochastic %K and %D were 34.90% and 41.31%, respectively, and the average true range (ATR) was 0.25. With the 14-day stochastic at 40.27% and the average true range at 0.23, the RSI (14) stands at 50.92%. The stock has reached -0.12 on the 9-day MACD Oscillator while the 14-day reading was at -0.05.
Citigroup downgraded Atara Biotherapeutics Inc. (NASDAQ: ATRA) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Atara Biotherapeutics Inc. (ATRA) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell ATRA, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is ATRA’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $31.00, with a median target of $20.00. Taking a look at these predictions, the average price target given by analysts for Atara Biotherapeutics Inc. (ATRA) stock is $16.27.